Endocyte Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Endocyte

Access the complete profile.

Endocyte Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	3000 Kent Avenue Suite A1 100 West Lafayette, IN 47906

Note: Revenues for privately held companies are statistical evaluations.


Endocyte's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Endocyte's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Endocyte is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Endocyte Annual Revenue and Growth Rate

Endocyte	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$100 - $500 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Endocyte's revenues are gauged from an analysis of company filings.

Endocyte's Income Statement (based on Industry Averages)

Endocyte P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Endocyte is developing and marketing. Endocyte doesn't have any recent trademark applications, indicating Endocyte is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
LUPLUSMEA Pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the purpose of increasing the effectiveness of other pharmaceutical products in the treatment of oncological diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer	01/14/2020
LUPLUSMIA Pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the purpose of increasing the effectiveness of other pharmaceutical products in the treatment of oncological diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer	01/14/2020
VIPLUSMA Pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the purpose of increasing the effectiveness of other pharmaceutical products in the treatment of oncological diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer	01/14/2020

See all trademarks and details in the Full Report.

Market Share of Endocyte's Largest Competitors

A competitive analysis shows these companies are in the same general field as Endocyte, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Endocyte. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
INOTIV	West Lafayette, IN	100
ENDOCYTE	West Lafayette, IN	78
PC KRAUSE & ASSOCIATES	West Lafayette, IN	7
IN SPACE	Lafayette, IN	1
NEXT OFFSET SOLUTIONS	West Lafayette, IN	1
VIBRONIX	West Lafayette, IN	1

Other Companies at 3000 Kent Avenue, West Lafayette IN

Company	Headquarters	Revenue ($ MM)
ADVANCED PROCESS COMBINATORICS I	West Lafayette, IN	100
GRIFFIN	West Lafayette, IN	0
GRIFFIN ANALYTICAL TECHNOLOGIES	West Lafayette, IN	0
FAST FORENSICS	W Lafayette, IN	0
INDEPENDENCE SCIENCE	West Lafayette, IN	0

Future Competition: Endocyte's Fastest Growing Competitors

These companies are in the same general field as Endocyte and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)